Compare TMDX & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TMDX | TRVI |
|---|---|---|
| Founded | 1998 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.6B |
| IPO Year | 2019 | 2019 |
| Metric | TMDX | TRVI |
|---|---|---|
| Price | $73.64 | $17.37 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 11 |
| Target Price | ★ $148.22 | $21.55 |
| AVG Volume (30 Days) | 969.8K | ★ 3.0M |
| Earning Date | 05-05-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 382.18 | 31.91 |
| EPS | ★ 0.20 | N/A |
| Revenue | ★ $605,494,000.00 | N/A |
| Revenue This Year | $24.25 | N/A |
| Revenue Next Year | $18.75 | N/A |
| P/E Ratio | $355.65 | ★ N/A |
| Revenue Growth | ★ 37.13 | N/A |
| 52 Week Low | $60.11 | $6.55 |
| 52 Week High | $156.00 | $20.22 |
| Indicator | TMDX | TRVI |
|---|---|---|
| Relative Strength Index (RSI) | 47.33 | 50.62 |
| Support Level | $64.87 | $10.07 |
| Resistance Level | $79.60 | $20.19 |
| Average True Range (ATR) | 3.13 | 1.40 |
| MACD | 0.02 | -0.23 |
| Stochastic Oscillator | 34.57 | 27.89 |
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System (OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization, and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.